



Australian Government

Department of Health, Disability and Ageing  
Therapeutic Goods Administration

Public Summary

|                                |                                               |
|--------------------------------|-----------------------------------------------|
| <b>Summary for ARTG Entry:</b> | 338394 NanoCelle D3 + K2                      |
| <b>ARTG entry for</b>          | Medicine Listed                               |
| <b>Sponsor</b>                 | Natural Bio Pty Limited                       |
| <b>Postal Address</b>          | PO Box 384, MONA VALE, NSW, 1660<br>Australia |
| <b>ARTG Start Date</b>         | 25/06/2020                                    |
| <b>Product Category</b>        | Medicine                                      |
| <b>Status</b>                  | Active                                        |
| <b>Approval Area</b>           | Listed Medicines                              |

Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

Products

1 . NanoCelle D3 + K2

|                     |                         |                       |           |
|---------------------|-------------------------|-----------------------|-----------|
| <b>Product Type</b> | Single Medicine Product | <b>Effective Date</b> | 3/10/2025 |
|---------------------|-------------------------|-----------------------|-----------|

Permitted Indications

Maintain/support general health and wellbeing  
Maintain/support bone health  
Aids/assists healthy bone development/growth/building  
Maintain/support bone mass/density/integrity  
Maintain/support bone strength  
Help maintain/support bone mineralisation  
Vitamin D helps calcium absorption (or words of like intent) and a diet deficient in calcium can lead to osteoporosis in later life  
Maintain/support healthy immune system function  
Helps stimulate a healthy immune system response  
Maintain/support (state vitamin/mineral/nutrient) levels in the body  
Helps prevent dietary (state vitamin/mineral/nutrient) deficiency  
Aid/assist/helps metabolism of (state vitamin/mineral/nutrient)

Indication Requirements

Product presentation must not imply or refer to bone disease or disorders e.g. rheumatoid arthritis, juvenile arthritis, debilitating osteoarthritis, osteoporosis. Note: this requirement is not intended to apply where the indications referring to osteoporosis specified in column 2 of the table in Part 2 of Schedule 1 to this instrument are also used.

Product presentation must not imply or refer to serious immunological diseases.

Label statement: [Vitamins/minerals/nutrients/dietary supplements] can only be of assistance if dietary intake is inadequate OR [Vitamins/minerals/nutrients/dietary supplements] should not replace a balanced diet (or words to that effect).

Indication only for use for medicines that contain vitamin D as an active ingredient. The medicines may only contain a maximum recommended daily dose of 25 micrograms or less of vitamin D and as a minimum, also contain at least 25% of the RDI in the recommended daily dose of vitamin D.

If product is indicated for supplementation, Label statement: [Vitamins/minerals/nutrients/dietary supplements] can only be of assistance if dietary intake is inadequate OR [Vitamins/minerals/nutrients/dietary supplements] should not replace a balanced diet (or words to that effect).

Standard Indications

No Standard Indications included on Record

Specific Indications

No Specific Indications included on Record



Australian Government

Department of Health, Disability and Ageing  
Therapeutic Goods Administration

Warnings

Contains sorbates

Vitamins can only be of assistance if the dietary vitamin intake is inadequate. OR Vitamin supplements should not replace a balanced diet.

Additional Product information

Pack Size/Poison information

Pack Size Poison Schedule

Components

1 . Formulation 1

Dosage Form Spray

Route of Administration Oral

Visual Identification

Active Ingredients

colecalfiferol 83.3 microgram/mL

menaquinone 7 150 microgram/mL

Other Ingredients (Excipients)

citric acid

glycerol

Maize Oil

Olive Oil

PEG-40 hydrogenated castor oil

Peppermint Oil

potassium sorbate

purified water

Steviol glycosides

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary